<h1 id="pesi-score-for-pulmonary-embolism">PESI Score for Pulmonary Embolism</h1>
<p><strong>Pulmonary Embolism Severity Index (PESI) score</strong></p>
<table>
<thead>
<tr>
<th>Finding</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>+1 per year</td>
</tr>
<tr>
<td>Male gender</td>
<td>+10</td>
</tr>
<tr>
<td>Cancer (history of or active)</td>
<td>+30</td>
</tr>
<tr>
<td>Heart failure</td>
<td>+10</td>
</tr>
<tr>
<td>Chronic lung disease</td>
<td>+10</td>
</tr>
<tr>
<td>Pulse ≥ 110 beats per min</td>
<td>+20</td>
</tr>
<tr>
<td>SBP &lt; 100 mmHg</td>
<td>+30</td>
</tr>
<tr>
<td>RR ≥ 30 breaths per min</td>
<td>+20</td>
</tr>
<tr>
<td>Temperature &lt; 36C</td>
<td>+20</td>
</tr>
<tr>
<td>Altered mental status</td>
<td>+60</td>
</tr>
<tr>
<td>Arterial oxygen saturation &lt; 90%</td>
<td>+20</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>Class</th>
<th>Point Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class I</td>
<td>&lt; 66</td>
</tr>
<tr>
<td>Class II</td>
<td>66-85</td>
</tr>
<tr>
<td>Class III</td>
<td>86-105</td>
</tr>
<tr>
<td>Class IV</td>
<td>106-125</td>
</tr>
<tr>
<td>Class V</td>
<td>&gt; 125</td>
</tr>
</tbody>
</table>
<h2 id="outpatient-treatment-of-pulmonary-embolism-otpe-trial">Outpatient Treatment of Pulmonary Embolism (OTPE) trial</h2>
<p><em>Study design:</em> Randomized, prospective, non-inferiority clinical trial of 19 ED’s (n = 344 patients) in Switzerland, France, Belgium, and USA looking at morbidity/mortality of PESI class I and II patients
<em>Exclusion criteria from study:</em></p>
<ul>
<li>Arterial hypoxemia (O2 saturation &lt; 90% on room air, or paO2 &lt; 60 mmHg)</li>
<li>SBP &lt; 100 mmHg</li>
<li>CP necessitating parental opioids</li>
<li>Active bleeding</li>
<li>High risk of bleeding defined as: CVA during preceding 10 days, GI bleeding in preceding 14 days, or platelets &lt; 75K </li>
<li>Severe renal failure (CrCl &lt; 30 mL per min)</li>
<li>Extreme obesity (body mass &gt; 150 kg)</li>
<li>History of heparin-induced thrombocytopenia or allergy to heparins</li>
<li>Therapeutic oral anticoagulation at time of PE diagnosis (INR ≥ 2)</li>
<li>Any barriers to treatment adherence (current EtOH abuse, illicit drug use, psychosis, dementia, homelessness)</li>
<li>Pregnancy, Imprisonment, Diagnosis of PE &gt; 23 hrs before time of screening</li>
</ul>
<table>
<thead>
<tr>
<th></th>
<th>Outpatient</th>
<th>Inpatient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recurrent venous thromboembolism ≤ 90 days</td>
<td>0.6% (1/171)</td>
<td>0% (0/168)</td>
</tr>
<tr>
<td>Death ≤ 90 days</td>
<td>0.6% (1/171)</td>
<td>0.6% (1/168)</td>
</tr>
<tr>
<td>Major bleeding ≤ 14 days</td>
<td>1.2% (2/171)</td>
<td>0% (0/168)</td>
</tr>
<tr>
<td>Major bleeding ≤ 90 days</td>
<td>1.8% (1/171)</td>
<td>0% (0/168)</td>
</tr>
</tbody>
</table>
<p><strong>Outpatient treatment </strong>= <strong><span class="drug">enoxaparin</span></strong> 1 mg/kg SQ BID to bridge into PO <strong><span class="drug">warfarin</span></strong> (target INR = 2)</p>
<p><strong>CONCLUSION</strong>: PE patients with PESI class I or II seem safe to manage as outpatients (be aware of exclusion criteria from study)</p>
<h2 id="references">References</h2>
<ul>
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21703676">Aujesky D, Roy PM, Verschuren F, Righini M, Osterwalder J, Egloff M, Renaud B, Verhamme P, Stone RA, Legall C, Sanchez O, Pugh NA, N&#39;gako A, Cornuz J, Hugli O, Beer HJ, Perrier A, Fine MJ, Yealy DM. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet. 2011 Jul 2;378(9785):41-8. doi: 10.1016/S0140-6736(11)60824-6. Epub 2011 Jun 22.</a></li>
</ul>
